Gain Therapeutics
GANX
19 hedge funds and large institutions have $9.77M invested in Gain Therapeutics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 11 closing their positions.
152% more capital invested
Capital invested by funds: $3.89M → $9.77M (+$5.89M)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
5.51% less ownership
Funds ownership: 12.07% → 6.56% (-5.5%)
32% less funds holding
Funds holding: 28 → 19 (-9)
82% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Gotham Asset Management
New York
|
+$421K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$111K |
| 3 |
Jones Financial Companies
Des Peres,
Missouri
|
+$58.4K |
| 4 |
SCP
Sandhill Capital Partners
Buffalo,
New York
|
+$19.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.91K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TIM
Timelo Investment Management
Aurora,
Ontario, Canada
|
-$775K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$576K |
| 3 |
HWM
Hohimer Wealth Management
Seattle,
Washington
|
-$422K |
| 4 |
CCC
Cable Car Capital
San Francisco,
California
|
-$186K |
| 5 |
CM
CM Management
Gulf Breeze,
Florida
|
-$115K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
26
Bridgeway Capital Management
Houston,
Texas
| – | -$51.2K | -40,000 | Closed |
|
|
VF
27
Virtu Financial
New York
| – | -$35K | -27,356 | Closed |
|
28
Millennium Management
New York
| – | -$29.9K | -23,373 | Closed |
|
|
GC
29
Gilbert & Cook
West Des Moines,
Iowa
| – | -$12.8K | -10,000 | Closed |
|
GANX Hedge Fund Activity: Q3 2024 in Review
19 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q3 2024, worth a combined $9.77M — up 152% from $3.89M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of GANX and 2 opened new positions — a net loss of 9 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was Gotham Asset Management, opening a new position worth an estimated $421K. The largest seller was Timelo Investment Management, exiting entirely with an estimated $775K sold.
- 19 institutional investors held Gain Therapeutics (GANX) as of Q3 2024, down from 28 in Q2 2024.
- Funds reported $9.77M of Gain Therapeutics stock for Q3 2024, up 152% quarter-over-quarter.
- 2 funds opened new Gain Therapeutics positions in Q3 2024 and 11 closed out, a net change of -9 holders.
- The largest Gain Therapeutics buyer in Q3 2024 was Gotham Asset Management, an estimated $421K added.
- The largest Gain Therapeutics seller in Q3 2024 was Timelo Investment Management, an estimated $775K sold.
Based on aggregated 13F filings for Q3 2024.